Industry Update: Biotechnology

IBiotech industry updatendustry Highlights

  • On March 4, 2021, Gilead Sciences, Inc. announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition
    provides Gilead with Hepcludex®, which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020.
  • On March 2, 2021, AbbVie agreed to sell off the biomanufacturing plant to China-based Pharmaron for $118.7 million in cash. The move comes shortly after Pharmaron bought out Absorption Systems in the U.S., paving the
    way for a cell and gene therapy platform.

Past Industry Updates

More Industry Reports